Journal
ONCOLOGIST
Volume 22, Issue 10, Pages 1178-1188Publisher
WILEY
DOI: 10.1634/theoncologist.2017-0064
Keywords
Cancer biomarkers; Gastrointestinal cancer; Noninvasive assay; Promoter methylation; Telomerase reverse transcriptase
Categories
Funding
- National Basic Research Program of China (grant 973 Program) [2012CB911202]
- National Natural Science Foundation of China [81372765, 81572515, 81472395, 81672522]
- Shandong Provincial Natural Science Foundation, China [ZR2011HM055, ZR2014HQ035, 2016ZDJS07A09]
- Swedish Cancer Society
- Swedish Research Council
- Cancer Society in Stockholm
- Karolinska Institutet
- Stockholm county council
Ask authors/readers for more resources
Background. There is a high demand for noninvasive screening tools for gastrointestinal cancer (GIC) detection, and GIC-specific markers are required for such purposes. It is established that induction of the telomerase reverse transcriptase gene (TERT) coupled with telomerase activation is essential for cancer development/progression and aberrant TERT promoter methylation of specific 5'-C-phosphate-G-3' (CpGs) has been linked to TERT induction in oncogenesis. Here we analyzed TERT promoter methylation in fecal samples from GIC patients and healthy adults and determined its value as a stool biomarker for GIC detection. Materials and Methods. Sixty-nine GIC patients (34 colorectal carcinoma and 35 gastric cancer) and 62 healthy adults were recruited and fecal samples were collected. Paired tumors and adjacent non-cancerous tissues from 34 patients and normal mucosa tissues from 12 healthy individuals were collected. TERT promoter methylation density was determined using pyrosequencing. Results. We identified two GIC-specific methylation sites at 2218 (CpG site 1) and 2210 (CpG site 2) in the TERT promoter in tumor tissues. Methylated TERT promoter CpG sites 1 and 2 were also detectable in patient stool, while only background levels were observed in healthy individuals. The overall sensitivity reached 52.2% (95% confidence interval [CI]: 48.3-56.0) for fecal methylated TERT promoter assays at 90% specificity, which was comparable to other known stool methylation markers for GIC detection. The combined assays of fecal TERT promoter methylation and occult blood (OB) significantly improved sensitivity and specificity in colorectal cancer (area under curves for methylation alone: 0.798, 95% CI: 0.707-0.889 vs. methylation+OB: 0.920, 95% CI: 0.859-0.981; p = .028), but not in gastric cancer. Conclusion. This proof-of-concept study suggests the feasibility of stool TERT promoter methylation analyses as an additional tool in noninvasive GIC screening.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available